Loading stock data…
CorMedix Inc. (CRMD)
$7.64-0.21 (-2.68%)
After Hours$7.59-0.05 (-0.65%)· Last close Jun 29
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CorMedix Inc. in the Healthcare sector is trading at $7.64 with a market capitalization of $646M. Wall Street consensus targets $15.20 (5 analysts), implying a +99.0% move over the next 12 months. The stock is currently near its 52-week low of $6.13, remaining 15.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +99.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $127.43M↓ | $128.62M↑ | $104.28M↑ | $39.74M↑ | $39.08M |
| Gross Profit | $105.12M↓ | $107.31M↑ | $93.08M↑ | $37.87M↑ | $37.48M |
| Operating Income | $63.66M↑ | $59.13M↑ | $51.35M↑ | $19.54M↓ | $20.13M |
| Net Income | $38.60M↑ | $14.02M↓ | $108.56M↑ | $19.83M↓ | $20.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$645.66M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.79
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
41.42%
Volume
Today's trading volume
1.26M
Recent News
CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook
CorMedix (CRMD) drew fresh attention after reporting robust Q1 2026 results, with DefenCath playing a central role in revenue and management lifting full year guidance while emphasizing progress in late stage pipeline programs. See our latest analysis for CorMedix. CorMedix’s recent Q1 update comes after a sharp 90 day share price return of 35.95% and a 30 day share price return of 14.70%, even though the year to date share price return is still down 28.78% and the 1 year total shareholder...
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why
CorMedix Inc. recently reported strong Q1 2026 results, with DefenCath driving a larger share of revenue and management raising full-year 2026 guidance while highlighting progress across late-stage programs such as REZZAYO ahead of a planned FDA submission in the second half of 2026. An interesting takeaway is that CorMedix emphasized continued operational momentum even as it prepares for the expiration of temporary dialysis add-on payments, underscoring management’s focus on sustaining...
CorMedix Inc. (CRMD) Reports Q1 2026 Results
CorMedix Inc. (NASDAQ:CRMD) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 net revenue of $127.4 million and net income of $38.6 million with adjusted EBITDA of $70.0 million. The firm said DefenCath contributed $97.5 million in revenue with higher outpatient dialysis utilization […]
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CorMedix (NASDAQ:CRMD) CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath uti
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?
In May 2026, CorMedix Inc. reported its first-quarter 2026 results, with sales rising to US$121.92 million and net income reaching US$38.6 million, and raised full-year net revenue guidance to US$325 million–US$345 million. Alongside the stronger earnings, CorMedix highlighted positive Phase III topline results for REZZAYO and ongoing progress in its late-stage anti-infective pipeline, underscoring how clinical developments are beginning to align with its expanded commercial footprint. We’ll...